Caris Life Sciences (CAI) priced 23.53M shares at $21.00. The deal priced above the $19.00-$20.00 range. BofA, JPMorgan and Goldman Sachs acted as joint book running managers for the offering. Caris describes itself as a “patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare.” Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to “analyze and further unravel the molecular complexity of disease” through comprehensive molecular profiling and the application of advanced AI and machine learning algorithms at scale, the company states.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter